12 Most Promising Biotech Stocks According to Wall Street Analysts

Page 5 of 10

6. BioNTech SE (NASDAQ:BNTX)

Analyst Upside: 47.23% 

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company specializing in mRNA-based vaccines and cancer immunotherapies. It is best known for its COVID-19 vaccine developed with Pfizer and focuses on personalized treatments tailored to genetic profiles.

BioNTech SE (NASDAQ:BNTX) is transitioning from reliance on COVID-19 vaccine revenues to focusing on its core cancer therapeutics. In Q4 2024, the company reported revenues of €1,190.0 million, down from €1,479.0 million in Q4 2023, while full-year revenues fell to €2,751.1 million from €3,819.0 million in 2023. The decline was mainly due to reduced demand for COVID-19 vaccines. Consequently, the company posted a net profit of €259.5 million for Q4 but reported a full-year net loss of €665.3 million compared to a €930.3 million profit in 2023.

Despite the revenue decline, BioNTech SE (NASDAQ:BNTX) maintains a strong financial position with €17.4 billion in cash and investments which provides stability for future growth. The corporation’s oncology pipeline is advancing rapidly, with over 20 active Phase 2 and Phase 3 trials. Its key programs include BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, and mRNA cancer immunotherapies leveraging its expertise in mRNA technology.

Analysts remain optimistic about BioNTech SE (NASDAQ:BNTX)’s future, with projected 2025 revenues between €1.7 billion and €2.2 billion. The company has made significant strides in oncology, initiating global Phase 3 trials for BNT327 in lung cancer and presenting promising data for triple-negative breast cancer at SABCS 2024. Additionally, the business expanded its pipeline through the acquisition of Biotheus, securing full control of BNT327. These strategic developments position the company for long-term growth in the oncology sector.

Page 5 of 10